Merckle invests in Ascentia

Published: 22-Aug-2002


German pharma company Merckle, of Ulm, has acquired a stake in Ascentia Pharma, a wholly owned subsidiary of Canadian biopharmaceutical group Horizon Sciences & Technology. The investment is further move to establish a global presence to support the development and future marketing of Merckle's novel arthritis treatment licofelone. Ascentia is already the licensee for licofelone in Canada and Mexico.

Proceeds from the financing will be used by Ascentia to advance the Phase III clinical trial programme for licofelone as well as to support research into licofelone's role in protecting bone cartilage in osteoarthritis. The clinical trials being undertaken by Ascentia are part of the global development programme and will support licensing in the US and Europe. Merckle already has a US placebo controlled trial under way with results expected early 2003. In June this year, the company announced the early results from the first European Phase III trials.

Licofelone is being seen as future competition for the traditional NSAIDs and COX-2 inhibitors owing to its potential to deliver similar or improved efficacy but with the possibility of fewer gastrointestinal side effects and lower risk of cardiovascular complications.

You may also like